Search - tctmd.com

Displaying 1 - 20 of 191

Sort: Relevancy | Date

News Conference News TCT 2016

TRANSFORM-OCT: Similar Early and Late Healing With Bioresorbable- and Durable-Polymer DES

Michael O'Riordan

November 02, 2016

Presentation TCT 2016

TCT 517: Fractional Flow Reserve Assessment of Coronary Artery Disease in Patients Undergoing TAVI.

Presenter: Alan C. Yeung, Tim P. van de Hoef

November 01, 2016

Presentation TCT 2016

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic AF Patient Who Requires PCI

Presenter: David P. Faxon, C. Michael Gibson, Deepak L. Bhatt

November 01, 2016

Presentation TCT 2016

When and Which Antiplatelet Agent Should be Dropped When Using Oral Anticoagulant Therapy?

Presenter: David P. Faxon, C. Michael Gibson, Roxana Mehran

November 01, 2016

Presentation TCT 2016

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

Presenter: David P. Faxon, C. Michael Gibson

November 01, 2016

Presentation TCT 2016

General Overview and Highlights of the North American Consensus Document on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

Presenter: David P. Faxon, C. Michael Gibson, Dominick J. Angiolillo

November 01, 2016

Presentation TCT 2016

European Guidelines on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

Presenter: David P. Faxon, C. Michael Gibson, Davide Capodanno

November 01, 2016

Presentation TCT 2016

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

Presenter: David P. Faxon, C. Michael Gibson, Freek W.A. Verheugt

November 01, 2016

Presentation TCT 2016

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus DAPT

Presenter: David P. Faxon, C. Michael Gibson, Christopher B. Granger

November 01, 2016

News Conference News TCT 2016

ReACT: Routine Angiographic Follow-up After PCI Does Not Lower Clinical Events

Michael O'Riordan

November 01, 2016

Presentation TCT 2016

COLOR: A Prospective, Multicenter Registry Evaluating the Relationship Between Lipid-Rich Plaque and Two-Year Outcomes After Stent Implantation in Patients With Coronary Artery Disease

Presenter: Howard C. Herrmann, Robert J. de Winter, Giora Weisz

November 01, 2016

News Conference News TCT 2016

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Yael L. Maxwell

October 31, 2016

Presentation TCT 2016

Trends in Outcomes of Treatment for LM Artery Disease: IRIS-MAIN Registry Data (N=5,020)

Presenter: Seung-Jung Park, Alan C. Yeung

October 31, 2016

Presentation TCT 2016

Trial #1 - The Essentials of ... ABSORB III Everolimus-Eluting Bioresorbable Vascular Scaffolds vs Everolimus-Eluting Metallic Stents in Coronary Artery Disease

Presenter: Sunil V. Rao, Harvey D. White, Stephen G. Ellis

October 31, 2016

Presentation TCT 2016

TCT 93: Near-Infrared Spectroscopy-Derived Lipid Core Burden Index Predicts Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease During 4.3 Year Follow-up

Presenter: Farouc Jaffer, Amir Lerman, Eric Boersma

October 31, 2016

Presentation TCT 2016

DELTA 2: A Prospective, Multicenter Registry Evaluating New Generation Drug-Eluting Stents in Patients with Obstructive Left Main Coronary Artery Disease

Presenter: Thomas F. Luscher, Patrick W. Serruys, Alaide Chieffo

October 31, 2016

Presentation TCT 2016

FUTURE-I: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Bo Xu

October 31, 2016

Presentation TCT 2016

TCT 47: Secular Trends in Characteristics, Treatments, and Outcomes in Patients With Unprotected Left Main Coronary Artery Disease Over Two Decades

Presenter: Javier Escaned, Christoph K. Naber, Duk-Woo Park

October 31, 2016

Presentation TCT 2016

FORTITUDE: Nine-Month Clinical, Angiographic, and OCT Results With an Amorphous PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Antonio Colombo

October 31, 2016

Presentation TCT 2016

MeRes-1: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

Presenter: Patrick W. Serruys, Joanna J. Wykrzykowska, Ashok Seth

October 31, 2016

Advertisement

TRANSFORM-OCT: Similar Early and Late Healing With Bioresorbable- and Durable-Polymer DES

TCT 517: Fractional Flow Reserve Assessment of Coronary Artery Disease in Patients Undergoing TAVI.

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic AF Patient Who Requires PCI

When and Which Antiplatelet Agent Should be Dropped When Using Oral Anticoagulant Therapy?

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

General Overview and Highlights of the North American Consensus Document on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

European Guidelines on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus DAPT

ReACT: Routine Angiographic Follow-up After PCI Does Not Lower Clinical Events

COLOR: A Prospective, Multicenter Registry Evaluating the Relationship Between Lipid-Rich Plaque and Two-Year Outcomes After Stent Implantation in Patients With Coronary Artery Disease

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Trends in Outcomes of Treatment for LM Artery Disease: IRIS-MAIN Registry Data (N=5,020)

Trial #1 - The Essentials of ... ABSORB III Everolimus-Eluting Bioresorbable Vascular Scaffolds vs Everolimus-Eluting Metallic Stents in Coronary Artery Disease

TCT 93: Near-Infrared Spectroscopy-Derived Lipid Core Burden Index Predicts Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease During 4.3 Year Follow-up

DELTA 2: A Prospective, Multicenter Registry Evaluating New Generation Drug-Eluting Stents in Patients with Obstructive Left Main Coronary Artery Disease

FUTURE-I: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

TCT 47: Secular Trends in Characteristics, Treatments, and Outcomes in Patients With Unprotected Left Main Coronary Artery Disease Over Two Decades

FORTITUDE: Nine-Month Clinical, Angiographic, and OCT Results With an Amorphous PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

MeRes-1: Six-Month Clinical, Angiographic, IVUS, and OCT Results With a Thin-Strut PLLA-Based Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content